RT Journal Article
SR Electronic
T1 Longitudinal Study on Seroprevalence and Immune Response to SARS-CoV-2 in a Population of Food and Retail Workers Through Transformation of ELISA Datasets
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.27.24301877
DO 10.1101/2024.01.27.24301877
A1 Djaïleb, Abdelhadi
A1 Parker, Megan-Faye
A1 Lavallée, Étienne
A1 Stuible, Matthew
A1 Durocher, Yves
A1 Thériault, Mathieu
A1 Santerre, Kim
A1 Gilbert, Caroline
A1 Boudreau, Denis
A1 Baz, Mariana
A1 Masson, Jean-Francois
A1 Langlois, Marc-André
A1 Trottier, Sylvie
A1 Quaglia, Daniela
A1 Pelletier, Joelle N.
YR 2024
UL http://medrxiv.org/content/early/2024/01/29/2024.01.27.24301877.abstract
AB Since the onset of the global pandemic caused by the emergence and spread of SARS-CoV-2 in early 2020, numerous studies have been conducted worldwide to understand our immune response to the virus. This study investigates the humoral response elicited by vaccination and by SARS-CoV-2 infection in the poorly studied food and retail workers in the Québec City area. The 1.5-year study period spans from early 2021, when vaccination became available in this region, to mid-2022, following waves of virulence due to the emergence of the first Omicron variants. Cross-correlated with data on workplace protective measures, pre-existing conditions, activities and other potentially relevant factors, this longitudinal study applies recently developed ELISA data transformation to our dataset to obtain normal distribution. This unlocked the possibility to use the ANOVA-Welsh method for statistical analysis to obtain a statistical perspective of the serological response. Our work allows the identification of factors contributing to statistically relevant differences in the humoral response of the cohort and strengthens the utility of the use of decentralized approaches to serological analysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Public Health Agency of Canada through the COVID‐19 Immunity Task Force (CITF) grant number 2021-HQ-000134. Viral antigen production at the National Research Council of Canada (NRC) and in-kind support to MAL were supported by the NRC Pandemic Response Challenge Program. This research was supported in part by Canada Research Chair CRC-2020-00171 to JNP and by the Sentinel North Research Chair at Universite Laval (funded by the Canada First Research Excellence Fund) as well as by the Canada Research Chair CRC-2022-00103 to MB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Comite ethique de la recherche of the Centre Hospitalier Universitaire de Quebec-Universite Laval gave ethical approval for this work with registration number 2021-5744I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.